Table 2.

Anti-PRP antibody levels and avidity index in Hib-vaccinated and -unvaccinated groups.

	Hib-vaccinated	Hib-unvaccinated	P
Anti-PRP IgG titer (IU/ml); No. (%); (95% CI)
No. of subjects	30	51
≥0.15	29 (96.67) (83.33–99.41)	28 (54.90) (41.38–67.73)	<0.001
≥1.0	25 (83.33) (66.44–92.66)	12 (23.53) (14.00–36.76)	<0.001
≥5.0	12 (40.0) (24.59–57.68)	3 (5.88) (2.02–15.92)	<0.001
GMT	2.95 (1.37–4.52)	0.35 (0.17–0.87)	0.003
PRP Avidity index (%), No. (%); (95% CI)
No. of subjects	29	26
≥50%	24 (82.76) (65.45–92.40)	19 (73.08) (53.92–86.30)	0.385
GMAI	65.13 (56.88–73.37)	61.09 (50.73–71.45)	0.936